Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1328-1340

  Gong, Aishen ^a   Chen, Xiaoyan ^a   Deng, Pan ^a   Zhong, Dafang ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Shanghai Hengrui Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 METHYLPIPERAZIN 1 YLMETHYL) N [6 METHYL 5 (4 PYRIDIN 3 YLPYRIMIDIN 2 YLAMINO)PYRIDIN 3 YL] 3 TRIFLUOROMETHYL BENZAMIDE; FLUMATINIB; HH GV678; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; DEMETHYLATION; DRUG METABOLISM; DRUG STRUCTURE; GLUCURONIDATION; HUMAN; HYDROLYSIS; HYDROXYLATION; OXIDATION; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADOLESCENT; ADULT; AGED; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; BENZAMIDES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; YOUNG ADULT;

EID: 77954889747     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032326     Document Type: Article

References (12)

1. E with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 21:1485-1496.
2. Deininger MW, Goldman JM, and Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
3. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, et al. (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503-1512.
4. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551. (Pubitemid 43882350)
5. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, and Ehlhardt WJ (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966-972. (Pubitemid 39096057)
6. Marull M and Rochat B (2006) Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple- quadrupole and linear ion trap mass spectrometers. J Mass Spectrom 41:390-404.
7. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172-183.
8. Sawyers CL (2001) Cancer treatment in the STI571 era: what will change? J Clin Oncol 19:13S-16S.
9. Seaton QF, Lawley CW, and Akers HA (1984) The reduction of aliphatic and aromatic N-oxides to the corresponding amines with titanium(III) chloride. Anal Biochem 138:238-241.
10. Steinberg M (2007) Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29:2289-2308.
11. Sun PY, Lv AF, Hu CY, and Wang WB (2008) inventors; Morris, Manning & Martin, LLP, assignee. Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof. U.S. patent 0,312,251, 2008 Dec 28.
12. Zhang H, Zhu M, Ray KL, Ma L, and Zhang D (2008) Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun Mass Spectrom 22:2082-2088.